All In Biotech

Drug Trial Radar · NCT07749157

A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis

An Open-Label, Multicenter, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

85

Planned (sponsor's estimate)

Start

Dec 14, 2026

Primary completion

Feb 28, 2031

Study completion Dec 28, 2031

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Aug 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and, pharmacodynamics (PD) of subcutaneously administered RO7845860 in participants with relapsing multiple sclerosis (RMS).

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • RO7845860Drug

    Participants will receive RO7845860 as an subcutaneous (SC) injection per the schedule in the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1, 2 and 3: Incidence and Severity of Adverse Events (AEs)Time frame: From Baseline up to approximately Week 96
  2. Part 1, 2 and 3: Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: From Baseline up to approximately Week 96

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.